Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT02960646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
Study identification
- NCT ID
- NCT02960646
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Aplastic Anemia
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Myelomonocytic Leukemia
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Lymphoblastic Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Plasma Cell Myeloma
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Plasma Cell Myeloma
- Therapy-Related Myelodysplastic Syndrome
Interventions
- Cyclophosphamide Drug
- Filgrastim Biological
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Rituximab Biological
- Tacrolimus Drug
- Total-Body Irradiation Radiation
Drug · Biological · Other + 2 more
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2017
- Primary completion
- Feb 12, 2023
- Completion
- Feb 12, 2023
- Last update posted
- Feb 15, 2023
2017 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02960646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02960646 live on ClinicalTrials.gov.